RxDoctor Payments Data

Michael Stevens, MD

Rheumatology · Dayton, OHNPI 1114901188

Payments from drug & device makers

$898in general payments, 2019–2025

Across 52 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$525
  • Novartis$90
  • Amgen$78
  • Pfizer$55
  • Genentech USA, Inc.$47
  • Johnson & Johnson$29
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$86096%
  • Education$202%
  • Gifts$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie31$525
Novartis5$90
Amgen4$78
Pfizer2$55
Genentech USA, Inc.4$47
Johnson & Johnson1$29
Ascend Therapeutics US, LLC1$18
Tonix Medicines, Inc.1$15
Mallinckrodt Hospital Products Inc.1$15
AstraZeneca1$13
Alkermes, Inc.1$12

How this compares

$898 in reported general payments places this provider in the 40th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$487,557
Medicare patients
263
Services billed
31,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept62$448,835
Enbrel SureclickEtanercept45$330,906
Humira(Cf) PenAdalimumab45$303,970
Enbrel MiniEtanercept19$144,822
RinvoqUpadacitinib13$102,184
Xeljanz XrTofacitinib Citrate15$86,105
MethotrexateMethotrexate Sodium596$9,791
Hydroxychloroquine Sulfate254$6,164
Prednisone605$4,452
Celecoxib48$3,388
Febuxostat12$2,543
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$1,432
Alendronate Sodium247$1,358
Leflunomide30$882
Nabumetone22$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$78$448,83562 claims
AbbVieRinvoq$525$102,18413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →